These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1314469)

  • 21. Monoclonal antibodies reveal in blocking reactions the antigenicity and antibody response of poliovirus.
    Uhlig H; Rutter G; Dernick R
    Dev Biol Stand; 1984; 57():187-91. PubMed ID: 6084610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
    Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
    Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
    Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein kinase activity in purified poliovirus particles and empty viral capsid preparations.
    Schärli CE; Koch G
    J Gen Virol; 1984 Jan; 65 ( Pt 1)():129-39. PubMed ID: 6319565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and on heat-inactivated virions.
    Blondel B; Akacem O; Crainic R; Couillin P; Horodniceanu F
    Virology; 1983 Apr; 126(2):707-10. PubMed ID: 6190311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunocytochemical localization of capsid-related particles in subcellular fractions of poliovirus-infected cells.
    Pfister T; Pasamontes L; Troxler M; Egger D; Bienz K
    Virology; 1992 Jun; 188(2):676-84. PubMed ID: 1316678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
    Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
    Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion.
    Wetz K; Willingmann P; Zeichhardt H; Habermehl KO
    Arch Virol; 1986; 91(3-4):207-20. PubMed ID: 3022677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
    J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epitope evolution in poliovirus maturation.
    Rombaut B; Vrijsen R; Boeyé A
    Arch Virol; 1983; 76(4):289-98. PubMed ID: 6194772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
    Ferguson M; Reed SE; Minor PD
    J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for several unrelated neutralization epitopes of poliovirus, type 1, strain Mahoney, provided by neutralization tests and quantitative enzyme-linked immunosorbent assay (ELISA).
    Uhlig H; Rutter G; Dernick R
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2809-12. PubMed ID: 6198443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.
    Evans DM; Minor PD; Schild GS; Almond JW
    Nature; 1983 Aug 4-10; 304(5925):459-62. PubMed ID: 6192344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between poliovirus neutralization and aggregation.
    Thomas AA; Vrijsen R; Boeyé A
    J Virol; 1986 Aug; 59(2):479-85. PubMed ID: 3016307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants.
    Huovilainen A; Hovi T; Kinnunen L; Takkinen K; Ferguson M; Minor P
    J Gen Virol; 1987 May; 68 ( Pt 5)():1373-8. PubMed ID: 2437244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
    Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
    Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production of monoclonal and monospecific antibodies against non-capsid proteins of poliovirus.
    Pasamontes L; Egger D; Bienz K
    J Gen Virol; 1986 Nov; 67 ( Pt 11)():2415-22. PubMed ID: 2431100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted.
    Couderc T; Martin A; Wychowski C; Girard M; Horaud F; Crainic R
    J Gen Virol; 1991 Apr; 72 ( Pt 4)():973-7. PubMed ID: 1707949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.